Gland Pharma will hold a meeting of the Board of Directors of the Company on 17 May 2021..

Powered by Capital Market - Live News

Gland Pharma has allotted 92,250 Equity shares of Rs.1/- each of the Company, fully paid up, on 16 March 2021 to employees on exercise of their Stock Options pursuant to Gland Pharma Employee Stock Options Scheme, 2019.

Consequently, the issued, subscribed and paid-up share capital of the Company stands increased to Rs. 163,592,923/- comprising of 163,592,923 Equity shares of face value Rs.1/- each.

Powered by Capital Market - Live News

This is the first of multiple partnerships being explored by Gland Pharma to leverage its manufacturing capacity and capabilities to support global supply of COVID-19 vaccine, the company said in a BSE filing made during market hours today.

The company will be leveraging its manufacturing capabilities for the production of Sputnik V COVID-19 vaccine.

Gland Pharma will utilise its Drug Substance and Drug Product facilities at its sites in Hyderabad. The production is expected to commence from third quarter of 2021 for estimated delivery starting from fourth quarter of 2021.

Under the terms of the agreement, Gland Pharma will first undertake technology transfer of the drug substance to its manufacturing facilities. After successful technology transfer, the company will then undertake manufacturing of drug substance and drug product filling into vials under aseptic conditions.

The company's expertise in manufacturing of sterile injectable at significant scale will support in establishing a stable supply of COVID-19 vaccine.

Hyderabad-based Gland Pharma is one of the largest and fastest growing injectable-focused companies, with a global footprint across 60 countries, including the United States, Europe, Canada, Australia, India and other markets. It operates primarily under a business to business (B2B) model and it engaged in development, manufacturing and marketing of complex injectables.

The company's standalone net profit rose 32.45% to Rs 204.11 crore on a 33.05% increase in net sales to Rs 859.42 crore in Q3 FY21 over Q3 FY20.

Powered by Capital Market - Live News

Gland Pharma has allotted 217,850 equity shares on 22 January 2021 under ESOS. Consequently, the paid-up equity share capital stands increased to 16,35,00,673 equity shares of face value of Rs 1 each.

Powered by Capital Market - Live News